Lamback, EB;
Chiarini, S;
Roposch, A;
Dattani, MT;
(2021)
Congenital growth hormone deficiency associated with hip dysplasia and Legg-Calve-Perthes disease.
Clinical Endocrinology
, 94
(4)
pp. 590-597.
10.1111/cen.14365.
Preview |
Text (Article)
Dattani_Manuscript Hip dysplasia final submitted version.pdf - Accepted Version Download (160kB) | Preview |
Preview |
Text (Tables)
Dattani_Final submitted Tables.pdf - Accepted Version Download (157kB) | Preview |
Abstract
Objective: Growth hormone deficiency (GHD) is usually treated with recombinant human GH (rhGH), and this has been rarely associated with hip disorders. We analysed the clinical data of patients with congenital GHD receiving rhGH who had associated hip dysplasia or Legg‐Calve‐Perthes disease (LCPD), with a view to determining whether the hip dysplasia was associated with the underlying disease or with rhGH treatment. / Design: We performed a retrospective analysis of paediatric and adolescent patients seen between 1992–2018 with congenital GHD and hip disorders. Data were collected through a review of the patients’ medical records and included demographics, clinical and imaging data, and the time frame between the onset of the symptoms related to the hip disorders and the onset of GH treatment. / Results: Of the 13 patients with hip disorders, hip dysplasia was present in ten patients and LCPD in three. Hip dysplasia was diagnosed before rhGH was initiated in 50% of cases. These patients had bilateral hip dysplasia and isolated GHD. LCPD was diagnosed in one patient before rhGH was commenced and did not progress. In two patients, LCPD was diagnosed after rhGH was started and did temporarily progress in one of them, but rhGH was not discontinued because LCPD did not seem to be related to rhGH treatment. / Conclusions: This study suggests that hip dysplasia could be a manifestation of an underlying GHD. Additionally, rhGH treatment may not necessarily be causative of LCPD.
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
